Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

Index by author

February 1, 2023; Volume 64,Issue 2
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

  1. Frye, Jennifer

    1. First-in-Humans Evaluation of Safety and Dosimetry of <sup>64</sup>Cu-LLP2A for PET Imaging
      Open Access
      First-in-Humans Evaluation of Safety and Dosimetry of 64Cu-LLP2A for PET Imaging
      Richard Laforest, Anchal Ghai, Tyler J. Fraum, Reiko Oyama, Jennifer Frye, Helen Kaemmerer, Greg Gaehle, Tom Voller, Cedric Mpoy, Buck E. Rogers, Mark Fiala, Kooresh I. Shoghi, Samuel Achilefu, Michael Rettig, Ravi Vij, John F. DiPersio, Sally Schwarz, Monica Shokeen and Farrokh Dehdashti
      Journal of Nuclear Medicine February 1, 2023, 64 (2) 320-328; DOI: https://doi.org/10.2967/jnumed.122.264349
  2. Fuchs, Jörg

    1. You have access
      First-in-Humans PET/MRI of In Vivo GD2 Expression in Osteosarcoma
      Nils Florian Trautwein, Gerald Reischl, Christian Seitz, Helmut Dittmann, Ferdinand Seith, Sophia Scheuermann, Tobias Feuchtinger, Frank Dombrowski, Rupert Handgretinger, Jörg Fuchs, Bernd Pichler, Christian la Fougère and Johannes Schwenck
      Journal of Nuclear Medicine February 1, 2023, 64 (2) 337-338; DOI: https://doi.org/10.2967/jnumed.122.264626
« Previous (Pages : 1 2 ... 2)next »
Back to top
PreviousNext

In this issue

Journal of Nuclear Medicine: 64 (2)
Journal of Nuclear Medicine
Vol. 64, Issue 2
February 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)

Issue highlights

  • Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients Receiving Concomitant 225Ac-DOTATATE–Targeted α-Therapy and Capecitabine: A Real-World-Scenario Management-Based Long-Term Outcome Study
  • 68Ga-DOTATATE Prepared from Cyclotron-Produced 68Ga: An Integrated Solution from Cyclotron Vault to Safety Assessment and Diagnostic Efficacy in Neuroendocrine Cancer Patients
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • MIRD Pamphlet No. 28, Part 1: MIRDcalc—A Software Tool for Medical Internal Radiation Dosimetry
  • Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine
  • Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
  • Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
  • High-Temporal-Resolution Lung Kinetic Modeling Using Total-Body Dynamic PET with Time-Delay and Dispersion Corrections
More...
SNMMI

© 2025 SNMMI

Powered by HighWire